Author:
Blanchard Ariel,Yarom Noam,Levi Lauren,Cheng Karis Kin Fong,Bossi Paolo,Zadik Yehuda,Elad Sharon,
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Lalla RV, Brennan MT, Gordon SM, Sonis ST, Rosenthal DI, Keefe DM (2019) Oral mucositis due to high-dose chemotherapy and/or head and neck radiation therapy. J Natl Cancer Inst Monogr 53:17–24
2. Elad S, Yarom N, Zadik Y, Kuten-Shorrer M, Sonis ST (2022) The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA Cancer J Clin 72:57–77
3. Hong CHL, Gueiros LA, Fulton JS, Cheng KKF, Kandwal A, Galiti D, Fall-Dickson JM, Johansen J, Ameringer S, Kataoka T, Weikel D, Eilers J, Ranna V, Vaddi A, Lalla RV, Bossi P, Elad S (2019) Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 27:3949–3967
4. Palifermin (marketed as Kepivance). In: Editor (ed)^(eds) Book Palifermin (marketed as Kepivance), City
5. Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P (2020) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 126:4423–4431